Theriva Biologics, Inc.TOVXNYSE
Loading
Asset Growth Under PressureDecelerating
Percentile Rank31
Year-over-Year Change
Year-over-year total asset growth rate
Latest
-13.94%
↓ 168% vs avg
Percentile
P31
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
20.60%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | -13.94% |
| Q2 2025 | 11.41% |
| Q1 2025 | -9.03% |
| Q4 2024 | -11.86% |
| Q3 2024 | -5.38% |
| Q2 2024 | -13.01% |
| Q1 2024 | -11.75% |
| Q4 2023 | -10.28% |
| Q3 2023 | -5.96% |
| Q2 2023 | -3.59% |
| Q1 2023 | -5.53% |
| Q4 2022 | -8.68% |
| Q3 2022 | -4.42% |
| Q2 2022 | -7.49% |
| Q1 2022 | 26.48% |
| Q4 2021 | -6.33% |
| Q3 2021 | -2.76% |
| Q2 2021 | -2.28% |
| Q1 2021 | 840.00% |
| Q4 2020 | 16.76% |
| Q3 2020 | -24.83% |
| Q2 2020 | -19.39% |
| Q1 2020 | -31.03% |
| Q4 2019 | -16.91% |
| Q3 2019 | -13.57% |
| Q2 2019 | -9.89% |
| Q1 2019 | -11.64% |
| Q4 2018 | 179.19% |
| Q3 2018 | 28.25% |
| Q2 2018 | -32.48% |
| Q1 2018 | -33.82% |
| Q4 2017 | -19.08% |
| Q3 2017 | 47.90% |
| Q2 2017 | -11.17% |
| Q1 2017 | -21.24% |
| Q4 2016 | 172.77% |
| Q3 2016 | -49.49% |
| Q2 2016 | -28.19% |
| Q1 2016 | -26.27% |
| Q4 2015 | -27.65% |